Targeted drug may prolong survival of patients with cervical cancer
Tuesday, March 11, 2014 - 12:30
in Health & Medicine
Erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer, a new clinical study has found. The results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.